Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study
Margherita Rimini(Vita-Salute San Raffaele University), Andrea Casadei‐Gardini(Vita-Salute San Raffaele University), Takuji Torimura(Omuta hospital), Francesca Salani(Scuola Superiore Sant'Anna), Kazuhiro Nouso(Okayama Prefecture), Mario Scartozzi(University of Cagliari), Yoichi Hiasa(Ehime University Hospital), Caterina Vivaldi(Scuola Superiore Sant'Anna), Shigeo Shimose(Kurume University), Atsushi Hiraoka(Ehime Prefectural Central Hospital), Stefano Cascinu(Vita-Salute San Raffaele University), Valentina Burgio(Vita-Salute San Raffaele University), Giorgio Astara(University of Cagliari), Sara Lonardi(Istituto Oncologico Veneto), Gianluca Masi(University of Pisa), Caterina Soldà(Istituto Oncologico Veneto), Toshifumi Tada(Himeji Red Cross Hospital), Toru Ishikawa(Saiseikai Niigata Daini Hospital), Eleonora Lai(University of Cagliari), Kouji Joko(Matsuyama Red Cross Hospital), Hideki Iwamoto, Koichi Takaguchi(Kagawa Prefectural Central Hospital), Tomotake Shirono(Kurume University), Noritomo Shimada(Otemae Hospital), Hironori Koga(Kurume University)
Cited by 46
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k